JP2002523370A - アポモルヒネ副作用の改善 - Google Patents
アポモルヒネ副作用の改善Info
- Publication number
- JP2002523370A JP2002523370A JP2000565888A JP2000565888A JP2002523370A JP 2002523370 A JP2002523370 A JP 2002523370A JP 2000565888 A JP2000565888 A JP 2000565888A JP 2000565888 A JP2000565888 A JP 2000565888A JP 2002523370 A JP2002523370 A JP 2002523370A
- Authority
- JP
- Japan
- Prior art keywords
- apomorphine
- dose
- patient
- administered
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004046 apomorphine Drugs 0.000 title claims abstract description 166
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title claims abstract description 153
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 230000006872 improvement Effects 0.000 title description 8
- 238000011287 therapeutic dose Methods 0.000 claims abstract description 25
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 35
- 230000036470 plasma concentration Effects 0.000 claims description 15
- 230000001568 sexual effect Effects 0.000 claims description 14
- 206010034010 Parkinsonism Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 206010041250 Social phobia Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000018052 penile erection Effects 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 abstract description 41
- 230000008673 vomiting Effects 0.000 abstract description 39
- 206010028813 Nausea Diseases 0.000 abstract description 22
- 230000008693 nausea Effects 0.000 abstract description 22
- 201000001881 impotence Diseases 0.000 abstract description 17
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 241001282135 Poromitra oscitans Species 0.000 abstract description 8
- 206010048232 Yawning Diseases 0.000 abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 abstract description 4
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 37
- 238000011282 treatment Methods 0.000 description 26
- 239000003826 tablet Substances 0.000 description 23
- 230000002411 adverse Effects 0.000 description 21
- 206010038776 Retching Diseases 0.000 description 17
- 230000006978 adaptation Effects 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 13
- 230000004044 response Effects 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001107 psychogenic effect Effects 0.000 description 6
- 230000036299 sexual function Effects 0.000 description 6
- 230000003474 anti-emetic effect Effects 0.000 description 5
- 239000002111 antiemetic agent Substances 0.000 description 5
- 230000001856 erectile effect Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 230000003044 adaptive effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 206010034319 Penile swelling Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 108091008690 chemoreceptors Proteins 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101100055824 Arabidopsis thaliana APO4 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940124975 inotropic drug Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/138,982 | 1998-08-24 | ||
| US09/138,982 US5994363A (en) | 1998-08-24 | 1998-08-24 | Amelioration of apomorphine adverse effects |
| PCT/US1999/014965 WO2000010567A1 (en) | 1998-08-24 | 1999-07-01 | Amelioration of apomorphine adverse effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002523370A true JP2002523370A (ja) | 2002-07-30 |
| JP2002523370A5 JP2002523370A5 (https=) | 2006-08-17 |
Family
ID=22484576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000565888A Pending JP2002523370A (ja) | 1998-08-24 | 1999-07-01 | アポモルヒネ副作用の改善 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5994363A (https=) |
| EP (1) | EP1105129A4 (https=) |
| JP (1) | JP2002523370A (https=) |
| CN (1) | CN1212841C (https=) |
| AU (1) | AU764068B2 (https=) |
| BR (1) | BR9913235A (https=) |
| CA (1) | CA2341673A1 (https=) |
| CZ (1) | CZ2001610A3 (https=) |
| HU (1) | HUP0201212A3 (https=) |
| IL (1) | IL141512A0 (https=) |
| NO (1) | NO20010899L (https=) |
| NZ (1) | NZ510359A (https=) |
| PL (1) | PL346273A1 (https=) |
| WO (1) | WO2000010567A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140072861A (ko) * | 2011-07-11 | 2014-06-13 | 브리타니아 파마슈티컬즈 리미티드 | 아포모르핀을 활성 성분으로 함유하는 신규 치료 조성물 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| BR0109515A (pt) | 2000-04-07 | 2004-08-10 | Tap Pharmaceutical Prod Inc | Derivados da apomorfina e métodos para seu uso |
| WO2001085013A2 (en) * | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| JP2004520389A (ja) * | 2001-02-08 | 2004-07-08 | ファルマシア・コーポレーション | 性的不全の治療のための早期効果発現薬剤 |
| ES2180446B1 (es) * | 2001-07-02 | 2004-01-16 | Esteve Labor Dr | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
| PL372290A1 (en) * | 2002-02-07 | 2005-07-11 | Pharmacia Corporation | Pharmaceutical dosage form for mucosal delivery |
| KR20050008658A (ko) * | 2002-03-19 | 2005-01-21 | 마이클 홀릭 | 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도 |
| CA2487577C (en) * | 2002-05-31 | 2014-11-18 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
| EP1558231A4 (en) * | 2002-10-03 | 2010-09-08 | Cypress Bioscience Inc | DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS |
| SI1610791T1 (sl) * | 2003-03-31 | 2011-05-31 | Titan Pharmaceuticals Inc | Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| RU2364400C2 (ru) * | 2003-04-14 | 2009-08-20 | Вектура Лтд | Фармацевтические композиции |
| AU2005232748A1 (en) * | 2004-04-13 | 2005-10-27 | The Mclean Hospital Corporation | R(-)-11-hydroxyaporphine derivatives and uses thereof |
| US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
| WO2009009083A1 (en) * | 2007-07-12 | 2009-01-15 | The Mclean Hospital Corporation | R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| PT2952191T (pt) | 2009-06-12 | 2018-11-30 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
| NZ612686A (en) | 2010-12-16 | 2015-11-27 | Cynapsus Therapeutics Inc | Sublingual films |
| JP7211706B2 (ja) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法 |
| IT202100009857A1 (it) | 2021-04-19 | 2022-10-19 | Univ Degli Studi Di Torino | Formulazione a rilascio controllato e prolungato di apomorfina |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09512273A (ja) * | 1994-04-22 | 1997-12-09 | ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド | 男性の勃起機能不全を改善するための剤形及び方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2818855A (en) * | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
| US3976780A (en) * | 1968-07-29 | 1976-08-24 | Societe D'etudes Scientifiques Et Industrielles L'ile-De-France | Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| AU1508183A (en) * | 1982-06-04 | 1983-12-08 | Beecham Group Plc | Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane |
| US4687773A (en) * | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
| US4772459A (en) * | 1986-09-09 | 1988-09-20 | Erbamont, Inc. | Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
| US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
-
1998
- 1998-08-24 US US09/138,982 patent/US5994363A/en not_active Expired - Fee Related
-
1999
- 1999-07-01 CN CNB998125210A patent/CN1212841C/zh not_active Expired - Fee Related
- 1999-07-01 EP EP99933642A patent/EP1105129A4/en not_active Withdrawn
- 1999-07-01 CA CA002341673A patent/CA2341673A1/en not_active Abandoned
- 1999-07-01 AU AU49651/99A patent/AU764068B2/en not_active Ceased
- 1999-07-01 BR BR9913235-4A patent/BR9913235A/pt not_active IP Right Cessation
- 1999-07-01 IL IL14151299A patent/IL141512A0/xx unknown
- 1999-07-01 CZ CZ2001610A patent/CZ2001610A3/cs unknown
- 1999-07-01 NZ NZ510359A patent/NZ510359A/xx unknown
- 1999-07-01 WO PCT/US1999/014965 patent/WO2000010567A1/en not_active Ceased
- 1999-07-01 JP JP2000565888A patent/JP2002523370A/ja active Pending
- 1999-07-01 HU HU0201212A patent/HUP0201212A3/hu unknown
- 1999-07-01 PL PL99346273A patent/PL346273A1/xx not_active Application Discontinuation
-
2001
- 2001-02-22 NO NO20010899A patent/NO20010899L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09512273A (ja) * | 1994-04-22 | 1997-12-09 | ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド | 男性の勃起機能不全を改善するための剤形及び方法 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6009065258, ＭＯＮＴＡＳＴＲＵＣ，Ｊ．Ｌ． ｅｔ ａｌ, "Ａ ｓｔｕｄｙ ｏｆ ｔｏｌｅｒａｎｃｅ ｔｏ ａｐｏｍｏｒｐｈｉｎｅ", Ｂｒ Ｊ Ｐｈａｒｍａｃｏｌ, 1996, Ｖｏｌ．１１７， Ｎｏ．５, ｐ．７８１−６ * |
| JPN6009065260, ＳＺＥＣＨＴＭＡＮ，Ｈ． ｅｔ ａｌ, "Ｓｅｎｓｉｔｉｚａｔｉｏｎ ａｎｄ ｔｏｌｅｒａｎｃｅ ｔｏ ａｐｏｍｏｒｐｈｉｎｅ ｉｎ ｍｅｎ： ｙａｗｎｉｎｇ， ｇｒｏｗｔｈ ｈｏｒｍｏｎｅ， ｎａｕｓｅａ， ａｎｄ ｈｙｐｅｒｔｈｅｒｍｉａ", Ｐｓｙｃｈｉａｔｒｙ Ｒｅｓ, 1988, Ｖｏｌ．２３， Ｎｏ．３, ｐ．２４５−５５ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140072861A (ko) * | 2011-07-11 | 2014-06-13 | 브리타니아 파마슈티컬즈 리미티드 | 아포모르핀을 활성 성분으로 함유하는 신규 치료 조성물 |
| KR101990897B1 (ko) | 2011-07-11 | 2019-06-19 | 브리타니아 파마슈티컬즈 리미티드 | 아포모르핀을 활성 성분으로 함유하는 신규 치료 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1324238A (zh) | 2001-11-28 |
| US5994363A (en) | 1999-11-30 |
| HUP0201212A3 (en) | 2004-12-28 |
| NO20010899D0 (no) | 2001-02-22 |
| NO20010899L (no) | 2001-04-24 |
| AU764068B2 (en) | 2003-08-07 |
| CN1212841C (zh) | 2005-08-03 |
| AU4965199A (en) | 2000-03-14 |
| PL346273A1 (en) | 2002-01-28 |
| EP1105129A4 (en) | 2003-11-12 |
| CA2341673A1 (en) | 2000-03-02 |
| HUP0201212A2 (en) | 2002-08-28 |
| CZ2001610A3 (cs) | 2002-03-13 |
| WO2000010567A1 (en) | 2000-03-02 |
| IL141512A0 (en) | 2002-03-10 |
| EP1105129A1 (en) | 2001-06-13 |
| NZ510359A (en) | 2003-06-30 |
| BR9913235A (pt) | 2001-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523370A (ja) | アポモルヒネ副作用の改善 | |
| JP6235962B2 (ja) | オキシコドンおよびナロキソンを含有する剤形 | |
| JP3310982B2 (ja) | 男性の勃起機能不全を改善するための剤形及び方法 | |
| US6395705B2 (en) | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists | |
| JP4097285B2 (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
| JP2002518439A (ja) | 男性勃起障害改善用のアポモルヒネ含有投薬形態 | |
| JP2003518063A (ja) | 麻薬および抗鬱剤から患者を離脱させるためのデキストロメトルファンおよびオキシダーゼ阻害剤の用法 | |
| EP4271376A1 (en) | Dexmedetomidine treatment regimens | |
| TW202308653A (zh) | 以神經活性類固醇進行治療的方法 | |
| JP2023521492A (ja) | ダリドレキサントの医学的用途 | |
| EP3454853B1 (en) | Treatment of alcoholism and depression using ibudilast | |
| Houtsmuller et al. | Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance | |
| JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
| MXPA01001877A (en) | Amelioration of apomorphine adverse effects | |
| HK1150754A (en) | Dosage form containing oxycodone and naloxone | |
| HK1014239B (en) | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100525 |